Search Results
Your search for The matches 34665 pages
Showing 23051 - 23100The Role of Music Therapy in Cancer Care
Music therapy, an established adjuvant to standard cancer care, is offered in a growing number of cancer centers throughout the United States and internationally. Defined by the American Music Therapy Association (AMTA) as “the evidence-based use of music interventions to accomplish individual...
Improving Management of Sexual Problems for Cancer Survivors
What do up to 60% of cancer survivors have in common? Answer: some type of long-term sexual dysfunction. How many cancer survivors seek professional help for sexual problems? Answer: less than 20%. Even when they do seek help, they may not be successful in finding professionals with expertise in...
AACR and CEO Margaret Foti, PhD, MD (hc) Honored With PHL Life Sciences Ultimate Solution Award
The American Association for Cancer Research (AACR) and its Chief Executive Officer, Margaret Foti, PhD, MD (hc), were honored with the PHL Life Sciences Ultimate Solution Award for their significant contributions to and impact on the field of cancer research. The award is presented annually by PHL ...
Why Patients’ Understanding of Their Prognosis Often Differs From Their Oncologists’
A recent study1 published in the Journal of Clinical Oncology (see “Breaking the ‘Conspiracy of Silence’” in this issue of The ASCO Post) found that just 1 in 20 patients with advanced, incurable cancer has sufficient understanding of his or her prognosis or life expectancy. Now, another new study ...
An Oncologist Battles a Preventable Epidemic: Cancer of the Cervix
Cervical cancer incidence and mortality rates—perhaps more than any other chronic disease—shine a grim spotlight on global disparities of care. It is one of the most preventable of human malignancies, yet it is the leading cause of cancer deaths in women around the world. It kills 260,000 women...
FDA Takes Action Against 55 Tobacco Retailers for Selling Newly Regulated Products to Minors
The U.S. Food and Drug Administration (FDA) announced on September 15 that it has taken action against 55 tobacco retailers by issuing the first warning letters for selling newly regulated tobacco products—such as e-cigarettes, e-liquids, and cigars—to minors. These actions come about a month after ...
I-SPY 2: Separating Contenders From Pretenders in Breast Cancer
With the expansion of our understanding of signaling pathways in normal cells and how they are co-opted or corrupted in malignancy, the number of potential antitumor agents to be tested has exploded, exposing the limitations of traditional antineoplastic drug development and challenging us to...
Nonwhite Organ Transplant Recipients Also at Heightened Risk for Skin Cancer
A new study from Drexel University College of Medicine suggests all organ transplant recipients, regardless of race, should receive routine, total-body screenings for skin cancer. Out of 259 nonwhite transplant recipients who were evaluated in the study, 19 skin cancer lesions were identified in...
High-Calcium, Low-Lactose Diet May Reduce Risk of Ovarian Cancer in African American Women
Research from Rutgers Cancer Institute of New Jersey and and other U.S. health and academic institutions shows a diet high in calcium and low in lactose may reduce the risk of ovarian cancer in African American women. The work, published by Qin et al in the British Journal of Cancer, also found sun ...
Comparison of Second-Line Treatments in Advanced Pancreatic Cancer After Gemcitabine-Based Chemotherapy
In the Canadian phase III PANCREOX trial reported in the Journal of Clinical Oncology, Gill et al found no benefit of modified FOLFOX6 (infusional fluorouracil [5-FU], leucovorin, and oxaliplatin) vs infusional 5-FU/leucovorin as second-line treatment in patients with advanced pancreatic cancer who ...
Survival Benefit Reported With Maintenance Olaparib in Platinum-Sensitive Recurrent Serous Ovarian Cancer With BRCA Mutation
Maintenance olaparib (Lynparza) appeared to be associated with an overall survival benefit vs placebo in women with platinum-sensitive serous ovarian cancer and BRCA1 and BRCA2 mutations, according to an updated analysis of a phase II trial reported in The Lancet Oncology by Ledermann et al....
Neoadjuvant Veliparib/Carboplatin and Neratinib ‘Graduate’ From Adaptive Randomization I-SPY 2 Trial in Early Breast Cancer
As reported by Hope S. Rugo, MD, and John W. Park, MD, both of the University of California, San Francisco, and colleagues in The New England Journal of Medicine, the multiarm adaptive randomization phase II I-SPY 2 trial has shown that the addition of veliparib/carboplatin and the addition of...
Maha H. Hussain, MD, Joins the Lurie Cancer Center
Maha H. Hussain, MD, has joined the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as the Associate Director for Clinical Sciences Research. Dr. Hussain will also serve as Co-Director of the Lurie Cancer Center’s Genitourinary Oncology Program, along with Edward Schaeffer,...
Julie E. Bauman, MD, MPH, Named Chief of Hematology/Oncology, Associate Director of Translational Research at UA Cancer Center
Julie E. Bauman, MD, MPH, a head and neck cancer specialist and physician-scientist, has been named Professor of Medicine and the new Chief of the Division of Hematology and Oncology at the University of Arizona (UA) College of Medicine–Tucson, as well as Associate Director of Translational...
ASCO, ASTRO, and SSO Issue Joint Update to Guideline on Postmastectomy Radiotherapy for Women With Breast Cancer
Earlier this month, ASCO, in collaboration with the American Society for Radiation Oncology (ASTRO) and the Society for Surgical Oncology (SSO), jointly issued an update to a clinical practice guideline for physicians treating women with breast cancer who have undergone a mastectomy. The update...
4th Annual Basser Global Prize Awarded to Women’s Cancer Geneticist Steven Narod, MD, FRCPC, PhD (hon), FRSC
The Basser Center for BRCA at Penn’s Abramson Cancer Center has announced the recipient of the 2016 Basser Global Prize is cancer geneticist Steven Narod, MD, FRCPC, PhD (hon), FRSC, Director of the Familial Breast Cancer Research Unit and a senior scientist at the Women’s College Hospital in...
FDA Grants Priority Review to Pembrolizumab Supplemental Biologics License Application for First-Line Treatment of Advanced NSCLC
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the first-line treatment of patients with advanced non–small cell lung cancer...
Lung Cancer Specialist Shares Clinical Pearls for Managing Stage IIIA Non–Small Cell Lung Cancer
Clinicians face a number of questions in evaluating and treating patients with stage IIIA non–small cell lung cancer (NSCLC). One expert in the field, Rafael Santana-Davila, MD, reviewed key issues in managing this disease in the Journal of Oncology Practice (JOP). The ASCO Post asked Dr....
Updated USPSTF Guidelines for Colorectal Cancer Screening: More Methods, More Challenges for Patients and Providers Alike
As reviewed in this issue of The ASCO Post, the U.S. Preventive Services Task Force (USPSTF) recently updated its guidelines for colorectal cancer screening1 from 2008 and has now included seven acceptable strategies, including direct-visualization modalities (ie, endoscopy and computed tomography...
New USPSTF Recommendations for Colorectal Cancer Screening
As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) has issued new recommendations for colorectal cancer screening.1 In brief, the USPSTF recommends colorectal cancer screening starting at age 50 years and continuing until age 75 years (grade A recommendation = “The USPSTF...
Testosterone-Related Genetic Mutation Associated With Poorer Survival in Prostate Cancer
A collaborative Cleveland Clinic–Mayo Clinic team of researchers has shown for the first time that patients with advanced prostate cancer are more likely to die earlier of their disease if they carry a specific testosterone-related genetic abnormality. The findings, published by Hearn et al in The...
Continuation of Docetaxel May Improve Survival in Metastatic Castration-Resistant Prostate Cancer
The number of docetaxel cycles completed was associated with improved overall survival among men with metastatic castration-resistant prostate cancer receiving docetaxel, prednisone, and lenalidomide (Revlimid) or docetaxel/prednisone, in the phase III Mainsail trial. de Morrée et al reported this ...
FDA Approves Ofatumumab in Combination With Fludarabine and Cyclophosphamide for Relapsed CLL
The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for the use of ofatumumab (Arzerra) in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). The application, which...
Everolimus in Advanced HER2-Positive Breast Cancer With PIK3CA Mutation, PTEN Loss, or Hyperactive PI3K Pathway
In an analysis of the phase III BOLERO-1 and -3 trials reported in the Journal of Clinical Oncology, Fabrice André, MD, of Institut Gustav-Roussy, Paris, France, and colleagues found that the addition of everolimus (Afinitor) to trastuzumab (Herceptin) and chemotherapy was associated with a...
ASH Presents Charles Mullighan, MBBS (Hons), MD, With the 2016 William Dameshek Prize
The American Society of Hematology (ASH) will present the 2016 William Dameshek Prize to Charles Mullighan, MBBS (Hons), MD, of St. Jude Children’s Research Hospital, for his leadership in defining the landscape of genetic alterations of acute lymphocytic leukemia (ALL), which has provided...
Novel Agents on the Horizon in Lymphoma
Attendees at the 2016 Pan Pacific Lymphoma Conference held July 18–22 in Koloa, Hawaii, got a peek at early data for a number of novel agents in the treatment of various lymphoma subtypes. The ASCO Post captured these findings. Denintuzumab Mafodotin in Diffuse Large B-Cell Lymphoma Denintuzumab...
Routine PET Surveillance Discouraged in Large Cell Lymphoma
There is no role for routine imaging as a means of following patients with large cell lymphoma, according to Bruce D. Cheson, MD, Deputy Chief of Hematology-Oncology and Professor of Medicine at Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC. “Routine...
Enhanced Survival With Implantable Scaffolds That Capture Metastatic Breast Cancer Cells in Vivo
A small device implanted under the skin may improve breast cancer survival by catching cancer cells, slowing the development of metastatic tumors in other organs, and allowing time to intervene with surgery or other therapies. These findings, reported by Rao et al in Cancer Research, suggest a path ...
Expert Point of View: Allen Cheng, MD, DDS; Susan D. McCammon, MD
The study findings by Dr. Buchakjian and colleagues suggest it may be time to revisit the significance of frozen margin status, according to one of the session co-moderators, Allen Cheng, MD, DDS, of the Providence Cancer Center and Head & Neck Surgical Associates, both in Portland, Oregon....
Specimen Margin Tops Frozen Margin as Prognostic Marker in Oral Cancer Surgery
Intraoperative frozen margins from the tumor bed help to assess the prognosis of oral cancer, but the permanent specimen margin remains king, according to a retrospective cohort study reported at the 9th International Conference on Head and Neck Cancer.1 Results indicated that the rate of local...
Expert Point of View: Benjamin L. Judson, MD
“This (adverse cardiac effects of chemotherapy) is a difficult problem to address because the side effects of chemotherapy in terms of its impact on the heart show up many years, sometimes decades, later. So that makes it harder to study and treat. It’s a real problem,” commented session...
Testosterone Therapy May Be Cardioprotective in Patients Undergoing Chemotherapy
The anabolic hormone testosterone may lessen the early adverse cardiovascular effects of chemotherapy and chemoradiation for advanced or recurrent cancer, according to a randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1 Among the patients studied,...
Reducing Drug Costs by Increasing Science-Driven Drug Discovery
For several years now, the American health-care system has been undergoing a transformation. Innovative ideas are being explored, new systems continue to be created, and millions of lives have been impacted. As health-care providers and research engines, academic institutions have an opportunity...
ASCO and AACI Initiative to Reduce Administrative and Regulatory Burden in Cancer Clinical Trials
As reported in the Journal of Clinical Oncology, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, and colleagues have provided a summary of the groundwork of an initiative by ASCO and the Association of American Cancer Institutes (AACI) to identify and reduce...
Immune Checkpoint Inhibitors March to First-Line Treatment in Advanced NSCLC
For the majority of patients who are diagnosed with advanced-stage non–small cell lung cancer (NSCLC), platinum-based doublets have been the standard of care for over 30 years. Recently, the immune checkpoint inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) demonstrated superior survival ...
Early Studies Examine Response of CML-Initiating Cells to Ezh2 Inhibition
Although targeted drugs like imatinib (Gleevec) have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time. New research conducted by scientists at Dana-Farber Cancer Institute...
Decisional Regret After Initial Treatment Decisions Among Parents of Children With Cancer
Racial/ethnic minority parents were more likely to express regret about initial cancer treatment decisions for their children, according to a study reported in the Journal of Clinical Oncology. Mack et al found that factors associated with less decisional regret included receiving high-quality...
Conflicting Interpretations of Genetic Findings on Multiplex Testing in Clinical Practice
In a study reported in the Journal of Clinical Oncology, Balmaña et al found that conflicting interpretations of findings on multiplex testing for cancer genes are fairly common among reporting laboratories and may have implications for medical management decisions. Study Details The study ...
‘Encouraging Survival Outcomes’ Reported With Combined Nivolumab and Ipilimumab in Advanced Melanoma
Hodi et al found “encouraging survival outcomes” with the addition of nivolumab to ipilimumab in patients with previously untreated unresectable stage III or IV melanoma, according to 2-year overall survival data in the phase II CheckMate 069 trial. These results were reported in The...
First-Line Nivolumab Alone and Combined With Platinum-Based Chemotherapy in Advanced NSCLC
The phase I CheckMate 012 study examined the effects of nivolumab (Opdivo) monotherapy and nivolumab combined with platinum-based doublets as first-line treatments in patients with advanced non–small cell lung cancer (NSCLC). Encouraging efficacy and safety findings were reported in the Journal...
Adolescent Girls With Leukemia May Not Be Screened for Pregnancy Before Beginning Chemotherapy
A new study indicates that adolescent females with acute leukemia have low rates of pregnancy screening prior to receiving chemotherapy that can cause birth defects. These findings were published by Rao et al in Cancer. Although many chemotherapy drugs can cause birth defects, there are no...
Good Outcome Reported With Unrelated-Donor Cord Blood Transplantation in Patients With Minimal Residual Disease
Survival with hematopoietic cell transplantation (HCT) from unrelated cord-blood donors was at least as good as that with HLA-matched unrelated donors and better than that with HLA-mismatched unrelated donors in patients with acute leukemia or myelodysplastic syndrome who had pretransplantation...
Overall Survival With Everolimus in Advanced Pancreatic Neuroendocrine Tumors in the RADIANT-3 Trial
As reported by Yao et al in the Journal of Clinical Oncology, the final overall survival analysis from the phase III RADIANT-3 trial showed a median survival of 44.0 months among patients with advanced pancreatic neuroendocrine tumors initially randomized to receive everolimus (Afinitor, Zortress)...
Vice President Biden Announces New Steps to Improve Clinical Trials Essential to Advancing the Cancer Moonshot
Today, Vice President Joe Biden announced a series of new steps focused on increasing access to information about clinical trials and improving the efficiency of our clinical research system. These steps include making it easier for participants to find clinical trial opportunities as quickly as...
CDC Finds Cancer Death Rates Among Children and Adolescents Declined by 20%, With Brain Cancer Topping Leukemia as Leading Cause of Death
New findings from the Centers for Disease Control and Prevention (CDC) show that the cancer death rate for children and adolescents aged 1 to 19 has been steadily declining since the mid-1970s and dropped by 20% from 1999 to 2014, the result of advances in therapy, especially for leukemia. During...
Joint Presence of Metabolic Syndrome and Obesity Seems to Be Associated With Poorer Survival in Early-Stage Colorectal Cancer
In a study in Kaiser Permanante patients reported in the Journal of Clinical Oncology, Cespedes Feliciano et al found that the joint presence of obesity and metabolic syndrome in those with early-stage colorectal cancer was associated with poorer overall and colorectal cancer–specific...
Study Suggests Role of Bilateral Oophorectomy in Preventing Premenopausal Breast Cancer in BRCA2- but Not BRCA1-Mutation Carriers
Bilateral oophorectomy was associated with prevention of premenopausal breast cancer in BRCA2- but not BRCA1-mutation carriers, according to a study reported by Kotsopoulos et al in the Journal of the National Cancer Institute. The study included 3,722 women with BRCA mutations in a prospective...
American Association for Cancer Research Releases 2016 Cancer Progress Report
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug...
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
A drop in the number of cancer cells detected in a patient’s blood could be the best indicator yet as to whether treatment for prostate cancer is working. A new study, published by Lorente et al in European Urology, shows that a 30% decline in a patient’s numbers of circulating tumor...
Everolimus Plus Bevacizumab Shows Activity in Advanced Non–Clear Cell Renal Cell Carcinoma
The combination of everolimus (Afinitor, Zortress) and bevacizumab (Avastin) was associated with clinical benefit in advanced non–clear cell renal cell carcinoma with a major papillary component, according to a single-center phase II trial reported by Voss et al in the Journal of Clinical...
